WASHINGTON, D.C.
Walk into almost any gas station, vape shop, or smoke shop in America and you'll find it sitting on the counter in a brightly colored pouch, marketed as a "natural" energy booster or a gentle mood lift — no prescription required, no age verification in most states, cheaper than a six-pack of beer. It's called kratom, and for years it existed in a kind of regulatory shadowland: not quite a supplement, not quite a drug, sold legally almost everywhere while federal agencies argued about what to do with it.
That shadowland is collapsing. A new peer-reviewed study published in the journal Addiction has confirmed what emergency rooms and poison control hotlines have been screaming for years: kratom-related reports to America's poison centers have exploded by roughly 6,500% since 2010, and the products causing the most damage today are far more dangerous than the plant your grandmother might have read about a decade ago.
THE NUMBERS THAT ALARMED RESEARCHERS
The study, which analyzed 8,919 kratom-related exposures reported to poison centers across all 50 states and the District of Columbia between 2010 and 2023, found that reports climbed from just 19 cases in 2010 to 1,242 cases in 2023 — an increase researchers calculated at approximately 6,500%.
The more disturbing trend is buried in the severity data. In 2010, poison centers recorded zero cases of severe medical outcomes tied to kratom. By 2023, that number had climbed to 158. Across the full 13-year study period, 13% of all reported kratom exposures resulted in what researchers classify as a "severe medical outcome" — a category that includes life-threatening effects, significant and lasting disability, or death.
And the trend isn't slowing down. Separate, more recent tracking shows that as of June 30, 2026, poison centers had already logged 3,190 reports of kratom and kratom-derivative exposures for the year — putting 2026 on pace for a 67.8% increase over 2025 alone. A parallel study led by researchers at UVA Health found that kratom-related poison center calls rose more than 1,200% between 2015 and 2025, with 2025 setting a new record of 3,434 reports, up from just 258 a decade earlier. Hospitalizations tied specifically to kratom rose even faster over that same window — up more than 1,150%, from 43 in 2015 to 538 in 2025.
Dr. Christopher Holstege, the UVA Health researcher who helped lead that analysis, didn't mince words about what he's seeing both in the national data and in his own emergency department. "The data reflects a concerning trend," Holstege said. "This trend found in the national data is also occurring in our local clinical practice, with more patients presenting to UVA Health following serious complications associated with kratom products."
WHAT KRATOM ACTUALLY IS — AND WHY IT'S CHANGED
Kratom comes from the leaves of Mitragyna speciosa, a tropical tree native to Southeast Asia, where it has a long history of traditional use as a mild stimulant when chewed in small doses. In the United States, it's sold as powders, capsules, teas, edibles, and liquid extracts, typically marketed with vague wellness language — energy, focus, mood support, pain relief, help easing opioid withdrawal — that has allowed it to skirt the kind of scrutiny applied to actual pharmaceuticals.
But the kratom showing up in American convenience stores today is often a different animal than the traditional leaf. The compound driving most of the recent alarm is 7-hydroxymitragynine, known as 7-OH — a minor, naturally occurring component of the kratom plant that manufacturers have learned to concentrate or synthesize into much more potent forms. Products boosted with high concentrations of 7-OH act directly on the brain's mu-opioid receptors — the same receptors targeted by morphine, oxycodone, and fentanyl — producing genuinely opioid-like effects: sedation, slowed breathing, and a dangerously slowed heart rate, especially at high doses or when mixed with alcohol, benzodiazepines, or other depressants.
In other words, what's being sold in a gas station pouch next to the energy drinks can, in concentrated form, function pharmacologically like an opioid — without the packaging, warnings, or regulatory oversight that would apply to one.
Health officials have also flagged that reported cases now include severe neurological complications, not just the seizures and cardiac problems documented in earlier research. Kratom exposures have been linked to liver damage, breathing failure, and irregular heart rhythms that in some cases have proven fatal.
THE REGULATORY SCRAMBLE
Federal regulators have been racing to respond, though the process has been anything but fast. On July 1, 2026, the Drug Enforcement Administration issued formal notice of its intent to temporarily place 7-OH into Schedule I — the most restrictive category under the Controlled Substances Act, reserved for substances deemed to have high abuse potential and no accepted medical use, the same category as heroin and LSD.
Crucially, the proposed scheduling is narrower than a blanket kratom ban. It targets concentrated and synthetic 7-OH products above a 0.05% threshold, while explicitly excluding natural kratom leaf that falls below that concentration. The distinction reflects a deliberate attempt by regulators to separate the traditional plant product — still legal and largely unregulated at the federal level — from the newer, engineered "extract" and "shot" products that critics say are essentially opioid analogs marketed to evade drug laws.
As of the DEA's notice, the scheduling action had not yet taken legal effect and could not take effect before August 5, 2026, at the earliest. The Department of Health and Human Services opened a public comment period on the proposed 0.05% threshold that ran through the end of July, drawing input from public health advocates, kratom industry representatives, and addiction medicine specialists with sharply divergent views on where the line should be drawn.
HHS and the FDA have publicly backed the DEA's move. In a joint statement, the agencies commended the action against what they described as "dangerous enhanced 7-OH products," citing mounting reports of misuse, dependence, and overdose, along with what they called growing evidence that concentrated 7-OH carries health risks comparable to powerful prescription opioids.
America's Poison Centers, the professional association representing the country's network of poison control hotlines, has gone further, issuing a formal health advisory warning clinicians and the public about serious illnesses tied to kratom and 7-OH products specifically — an escalation from years of more routine surveillance reporting.
THE INDUSTRY PUSHBACK
Not everyone agrees the crackdown is warranted, or that it's being calibrated correctly. Kratom industry advocates have long argued that the plant, used responsibly in its traditional leaf form, poses far less risk than the numbers suggest, and that much of the harm being reported traces back specifically to the newer high-concentration 7-OH products rather than kratom broadly. Some public health researchers have echoed a version of that concern, worried that lumping all kratom products together in public messaging could obscure the more urgent problem: unregulated manufacturers spiking products with concentrated 7-OH, adulterants, or other substances entirely, sold under the same "kratom" branding consumers have come to see as benign.
That distinction matters enormously for how consumers should think about risk. A product labeled "kratom" today could be anything from a mild traditional leaf powder to a highly concentrated opioid-like extract engineered for maximum potency — and current labeling requirements in most states do little to help a shopper tell the difference.
WHAT THIS MEANS FOR YOU
If you or someone in your household uses kratom products — whether for pain, energy, mood, or to manage opioid withdrawal — there are a few things worth knowing right now. First, products marketed as "enhanced," "extract," "shot," or specifically labeled with high 7-OH content carry meaningfully higher risk of the kind of severe outcomes — seizures, breathing problems, heart rhythm changes — driving the poison center surge, compared to traditional leaf powder or capsules.
Second, combining kratom or 7-OH products with alcohol, benzodiazepines (like Xanax or Valium), or other sedatives significantly increases the danger of slowed breathing and overdose, mirroring the risk profile of combining traditional opioids with those same substances.
Third, if you're using kratom to manage opioid withdrawal or chronic pain without medical supervision, it's worth having an honest conversation with a doctor. Because kratom exists in a regulatory gray zone, many users don't realize they can develop physical dependence on it, complete with withdrawal symptoms if they stop — a pattern addiction medicine specialists say is becoming more common as concentrated products flood the market.
Finally, watch for the regulatory picture to keep shifting. The DEA's proposed scheduling of 7-OH remains in flux, and depending on how the final rule is written, some products currently sitting on convenience store shelves could become federally controlled substances in the coming months. If you or a family member relies on a specific product, it's worth checking its 7-OH concentration and staying alert to news about the final rule.
THE BOTTOM LINE
A plant sold for years as a harmless "natural" alternative has quietly become one of the fastest-growing sources of poison center calls in the country, and the products driving that surge — concentrated 7-OH extracts acting on the same brain receptors as prescription opioids — are far more potent than most consumers realize. With federal regulators racing to schedule the compound and public health officials issuing formal warnings, the gas-station shelf kratom occupies today may look very different by the time winter arrives. Until then, the data is unambiguous: more Americans than ever are ending up in emergency rooms and on the phone with poison control because of a product most of them assumed was safe.
